NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug Conjugates

NextCure Inc NXTC and LegoChem Biosciences Inc announced a collaboration and co-development agreement to generate a B7-H4 antibody-drug conjugate (ADC) and options for two additional targets.
The B7-H4 ADC will utilize NextCure's B7-H4 antibody and LCB's ConjuAllTM ADC technology.
Under the terms of the agreement, both parties will equally share the costs to develop the molecules and profits on commercialized products.
Related: NextCure Launches Early-Stage Study For NC762 In Solid Tumor Settings.
The parties will utilize their respective product development capabilities to generate the B7-H4 ADC and advance it to the clinic.
In addition, there are options for the parties to nominate two additional targets for ADC development beyond B7-H4.
"We are excited to work with LCB and apply ConjuAllTM, a leading ADC technology, to add a new treatment modality to our B7-H4 program," said Timothy Mayer, NextCure's Chief Operating Officer.
Price Action: NXTC shares closed lower by 1.78% at $1.66 on Tuesday.